Biologics Spine Vivex Biologics, Inc. Completes Subject Enrollment for its ASCEND Trial Evaluating VIA Disc NP™ for Symptomatic Disc Degeneration byJosh SandbergJuly 29, 2025
Spine Top Stories Spine BioPharma, Inc. Announces Completion of Enrollment for Phase 3 Clinical Trial of SB-01 to Address Chronic Low Back Pain byJosh SandbergSeptember 24, 2024
Regulatory Spine Top Stories Landmark Clinical Study Demonstrates Superiority of 3-Level Circumferential Cervical Fusion Over Anterior Cervical Fusion Alone byJosh SandbergJuly 11, 2024
Biologics Spine Bone Biologics Receives Human Research Ethics Committee Approval to Begin Pilot Clinical Trial with NB1 in Spinal Fusion Patients in Australia byJosh SandbergApril 11, 2023
Financial Spine Global Degenerative Disc Disease Treatment Market to Surpass US$ 4,525.9 Million by 2030, Says Coherent Market Insights (CMI) byJosh SandbergFebruary 13, 2023
Biologics Spine Bone Biologics Advances Preparations for NB1 Pilot Clinical Trial with Engagement of Contract Research Organization byJosh SandbergJanuary 26, 2023
Spine Top Stories DiscGenics Announces Positive Two-Year Clinical Data from Study of Discogenic Progenitor Cell Therapy for Degenerative Disc Disease byJosh SandbergJanuary 23, 2023
Spine Top Stories Spinal Stabilization Technologies Ltd. Announces Start of LOPAIN 2 Clinical Trial in South America for Lumbar Degenerative Disc Disease byJosh SandbergNovember 16, 2022
Biologics Spine Top Stories Spine BioPharma Announces First Patient Treated in U.S. Phase 3 Clinical Study byChris StewartSeptember 7, 2022
Regulatory Spine Top Stories Spine BioPharma Initiating U.S. Phase 3 Clinical Study byJosh SandbergMay 11, 2022
